share_log

RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $40 Price Target

Benzinga ·  Jul 22 21:56  · Ratings

RBC Capital analyst Luca Issi reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and maintains $40 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment